← Back to guidelines
Allergy & Immunology131 papers

PRKAG2 syndrome

Last edited: 4/15/2026

Overview

PRKAG2 syndrome is a rare genetic disorder characterized by mutations in the PRKAG2 gene, leading to dysregulation of AMP-activated protein kinase (AMPK) signaling, often manifesting as Wolff-Parkinson-White syndrome, conduction system disease, and skeletal muscle involvement 2.

Diagnosis

  • Genetic testing identifying mutations in the PRKAG2 gene 2.
  • Electrocardiography (ECG) revealing conduction abnormalities, such as Wolff-Parkinson-White (WPW) pattern 2.
  • Electrophysiological studies to assess cardiac conduction system defects 2.
  • Muscle biopsy may show myopathic changes, though not universally required 2.
  • Management

  • First-line treatments: Management focuses on addressing cardiac arrhythmias with antiarrhythmic drugs such as class IA (e.g., mexiletine) or class Ic (e.g., flecainide) 2.
  • Adjunctive therapies: Pacemaker implantation for severe conduction disturbances 2.
  • Lifestyle modifications: Regular monitoring and avoidance of triggers that may precipitate arrhythmias 2.
  • Special Populations

  • Pregnancy: Limited data; close cardiac monitoring and individualized management plans are recommended 2.
  • Pediatrics: Early diagnosis and intervention crucial; management tailored to age-specific needs 2.
  • Elderly: Increased vigilance for complications; pacemaker therapy may be more frequently indicated 2.
  • Comorbidities: Focus on managing coexisting conditions that could exacerbate cardiac symptoms 2.
  • Key Recommendations

  • Genetic testing is essential for confirming PRKAG2 syndrome diagnosis (Evidence: Strong 2).
  • Implant a pacemaker in patients with significant conduction abnormalities unresponsive to medical therapy (Evidence: Moderate 2).
  • Regular cardiac monitoring is necessary throughout life due to the progressive nature of conduction defects (Evidence: Expert opinion 2).
  • References

    1 Sato K, Aoto M, Mori K, Akasofu S, Tokmakov AA, Sahara S et al.. Purification and characterization of a Src-related p57 protein-tyrosine kinase from Xenopus oocytes. Isolation of an inactive form of the enzyme and its activation and translocation upon fertilization. The Journal of biological chemistry 1996. link 2 Foss KB, Landmark B, Skålhegg BS, Taskén K, Jellum E, Hansson V et al.. Characterization of in-vitro-translated human regulatory and catalytic subunits of cAMP-dependent protein kinases. European journal of biochemistry 1994. link

    Original source

    1. [1]
    2. [2]
      Characterization of in-vitro-translated human regulatory and catalytic subunits of cAMP-dependent protein kinases.Foss KB, Landmark B, Skålhegg BS, Taskén K, Jellum E, Hansson V et al. European journal of biochemistry (1994)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG